Evidence that mTOR suppression leads to a dormant state in tumor cells followed by translational reprogramming should be taken into account under cancer treatment with dual mTORC1/2 inhibitors to prevent possible fatal consequences in patients. The gene discussed is MTOR; the disease is neoplasm.